Hemostemix (CVE:HEM) Shares Up 29.4% – What’s Next?

by · The Cerbat Gem

Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 29.4% during mid-day trading on Saturday . The stock traded as high as C$0.11 and last traded at C$0.11. 602,760 shares were traded during mid-day trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.

Hemostemix Trading Up 29.4%

The company has a fifty day simple moving average of C$0.09 and a two-hundred day simple moving average of C$0.10. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The company has a market cap of C$20.73 million, a PE ratio of -4.07 and a beta of 1.25.

Hemostemix Company Profile

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Read More